About SCYNEXIS (NASDAQ:SCYX)
SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:SCYX
- CUSIP: N/A
- Web: www.scynexis.com
Capitalization:- Market Cap: $53.15 million
- Outstanding Shares: 26,722,000
Average Prices:- 50 Day Moving Avg: $2.21
- 200 Day Moving Avg: $2.02
- 52 Week Range: $1.52 - $4.21
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.85
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $256,999.00
- Price / Sales: 207.95
- Book Value: $1.20 per share
- Price / Book: 1.67
Profitability:- EBITDA: ($25,040,000.00)
- Net Margins: -9,648.47%
- Return on Equity: -64.04%
- Return on Assets: -37.19%
Debt:- Debt-to-Equity Ratio: 0.41%
- Current Ratio: 10.89%
- Quick Ratio: 10.89%
Misc:- Average Volume: 256,188 shs.
- Beta: 0.42
- Short Ratio: 12.29
Frequently Asked Questions for SCYNEXIS (NASDAQ:SCYX)
What is SCYNEXIS's stock symbol?
SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."
How were SCYNEXIS's earnings last quarter?
SCYNEXIS, Inc. (NASDAQ:SCYX) issued its quarterly earnings results on Monday, August, 8th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by $0.04. The business earned $0.06 million during the quarter. SCYNEXIS had a negative net margin of 9,648.47% and a negative return on equity of 64.04%. View SCYNEXIS's Earnings History.
Where is SCYNEXIS's stock going? Where will SCYNEXIS's stock price be in 2017?
6 brokers have issued 1 year price objectives for SCYNEXIS's shares. Their forecasts range from $7.00 to $15.00. On average, they anticipate SCYNEXIS's stock price to reach $11.00 in the next year. View Analyst Ratings for SCYNEXIS.
What are analysts saying about SCYNEXIS stock?
Here are some recent quotes from research analysts about SCYNEXIS stock:
- 1. According to Zacks Investment Research, "SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. It also provides contract research and development services. SCYNEXIS, Inc. is headquartered in Durham, North Carolina. " (10/10/2017)
- 2. Guggenheim analysts commented, "Post 4Q16, we remain positive on SCYX because we believe SCY-078 still has a viable future and is differentiated as a potential IV-oral stepdown therapy for invasive fungal infections, an area of unmet need that is difficult to treat. While the delay in the IV formulation is not ideal, SCYX was not going to move forward with the high doses where the thrombotic events were experienced. SCYX will meet the FDA in 2Q17 to discuss a path forward for the IV formulation. Importantly, oral SCY-078 development is not affected, and SCYX continues to move forward with the rest of its pipeline assets as well." (3/14/2017)
Who are some of SCYNEXIS's key competitors?
Some companies that are related to SCYNEXIS include Aralez Pharmaceuticals (ARLZ), Female Health Company (The) (VERU), BioLife Solutions (BLFS), Diurnal Group PLC (DNL), Evoke Pharma (EVOK), Concordia International Corp. (CXRX), Juniper Pharmaceuticals (JNP), Histogenics Corporation (HSGX), Amryt Pharma PLC (AMYT), Intellipharmaceutics International (IPCI), Pernix Therapeutics Holdings (PTX), Cellectar Biosciences (CLRB), Apricus Biosciences (APRI), Immune Pharmaceuticals (IMNP), Venture Life Group PLC (VLG), Eyegate Pharmaceuticals (EYEG), Neuralstem (CUR) and Galena Biopharma (GALE).
Who are SCYNEXIS's key executives?
SCYNEXIS's management team includes the folowing people:
- Pamela J. Kirby Ph.D., Chairman of the Board
- Marco Taglietti M.D., President, Chief Executive Officer, Director
- Eric S. Francois, Chief Financial Officer
- David Angulo M.D., Chief Medical Officer
- Laurent Arthaud, Director
- Steven C. Gilman Ph.D., Director
- Ann F. Hanham Ph.D., Director
- David C. Hastings, Director
- Patrick J. Langlois Ph.D., Director
How do I buy SCYNEXIS stock?
Shares of SCYNEXIS can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is SCYNEXIS's stock price today?
One share of SCYNEXIS stock can currently be purchased for approximately $2.00.
MarketBeat Community Rating for SCYNEXIS (NASDAQ SCYX)MarketBeat's community ratings are surveys of what our community members think about SCYNEXIS and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for SCYNEXIS (NASDAQ:SCYX) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 5 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.83) |
| Consensus Price Target: | $11.00 (450.00% upside) |
Consensus Price Target History for SCYNEXIS (NASDAQ:SCYX)
Analysts' Ratings History for SCYNEXIS (NASDAQ:SCYX)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/16/2017 | HC Wainwright | Set Price Target | Buy | $14.00 | High |  |
| 8/7/2017 | Roth Capital | Set Price Target | Buy | $9.00 | Medium | |
| 5/30/2017 | Aegis | Reiterated Rating | Buy | | Medium | |
| 5/9/2017 | Needham & Company LLC | Downgrade | Buy -> Hold | | High | |
| 3/14/2017 | Guggenheim | Reiterated Rating | Buy | $15.00 | High | |
| 3/3/2017 | Royal Bank Of Canada | Reiterated Rating | Outperform | $15.00 -> $11.00 | N/A | |
| 10/7/2016 | WBB Securities | Upgrade | Buy -> Strong-Buy | $8.00 | N/A | |
| 10/3/2016 | Brean Capital | Initiated Coverage | Buy | $16.00 | N/A | |
| 6/9/2016 | Canaccord Genuity | Reiterated Rating | Buy | | N/A | |
(Data available from 10/18/2015 forward)
Earnings History for SCYNEXIS (NASDAQ:SCYX)Earnings History by Quarter for SCYNEXIS (NASDAQ SCYX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/8/2016 | Q216 | ($0.52) | ($0.56) | | $0.06 million | View | N/A | |
| 5/9/2016 | Q116 | ($0.63) | ($0.52) | | $0.06 million | View | N/A | |
| 11/13/2015 | Q315 | ($0.62) | ($0.60) | | $0.06 million | View | N/A | |
| 5/15/2015 | Q115 | ($0.43) | ($0.75) | $4.20 million | $2.31 million | View | N/A | |
| 3/30/2015 | | ($0.71) | ($0.45) | | $5.30 million | View | N/A | |
| 11/13/2014 | | ($0.53) | ($0.45) | | $4.38 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for SCYNEXIS (NASDAQ:SCYX)Current Year EPS Consensus Estimate: $-1.17 EPS
Next Year EPS Consensus Estimate: $-1.08 EPS
Dividend History for SCYNEXIS (NASDAQ:SCYX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for SCYNEXIS (NASDAQ:SCYX)Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 36.75%
Insider Trades by Quarter for SCYNEXIS (NASDAQ:SCYX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/22/2017 | Marco Taglietti | CEO | Buy | 10,000 | $2.23 | $22,300.00 | |
| 8/23/2017 | Marco Taglietti | CEO | Buy | 5,000 | $1.85 | $9,250.00 | |
| 8/15/2017 | Marco Taglietti | CEO | Buy | 10,000 | $1.61 | $16,100.00 | |
| 8/11/2017 | Gonzalez David Angulo | Insider | Buy | 10,000 | $1.55 | $15,500.00 | |
| 6/21/2017 | David C Hastings | Director | Buy | 20,000 | $1.75 | $35,000.00 | |
| 5/12/2017 | Gonzalez David Angulo | Insider | Buy | 15,000 | $1.70 | $25,500.00 | |
| 5/12/2017 | Marco Taglietti | CEO | Buy | 25,000 | $1.69 | $42,250.00 | |
| 12/21/2016 | Marco Taglietti | CEO | Buy | 25,000 | $3.30 | $82,500.00 | |
| 12/16/2016 | Gonzalez David Angulo | Insider | Buy | 4,000 | $3.25 | $13,000.00 | |
| 9/15/2016 | Patrick Machado | Director | Buy | 40,000 | $2.94 | $117,600.00 | |
| 6/30/2016 | Gonzalez David Angulo | Insider | Buy | 36,950 | $2.22 | $82,029.00 | |
| 6/24/2016 | Eric Francois | CFO | Buy | 15,000 | $2.39 | $35,850.00 | |
| 6/24/2016 | Guy Macdonald | Director | Buy | 40,000 | $2.39 | $95,600.00 | |
| 6/24/2016 | Marco Taglietti | CEO | Buy | 100,000 | $2.39 | $239,000.00 | |
| 5/25/2016 | Ann Hanham | Director | Buy | 4,225 | $3.64 | $15,379.00 | |
| 5/25/2016 | Marco Taglietti | CEO | Buy | 5,754 | $3.26 | $18,758.04 | |
| 5/24/2016 | Marco Taglietti | CEO | Buy | 5,500 | $3.37 | $18,535.00 | |
| 5/23/2016 | Marco Taglietti | CEO | Buy | 7,500 | $3.14 | $23,550.00 | |
| 5/19/2016 | Marco Taglietti | CEO | Buy | 6,000 | $3.07 | $18,420.00 | |
| 11/24/2015 | Marco Taglietti | CEO | Buy | 22,733 | $6.79 | $154,357.07 | |
| 8/31/2015 | Marco Taglietti | CEO | Buy | 25,000 | $7.82 | $195,500.00 | |
| 8/28/2015 | Marco Taglietti | CEO | Buy | 2,267 | $7.08 | $16,050.36 | |
| 8/26/2015 | Marco Taglietti | CEO | Buy | 50,000 | $7.07 | $353,500.00 | |
| 5/7/2014 | Jean-Yves Nothias | Director | Buy | 50,000 | $10.00 | $500,000.00 | |
| 5/7/2014 | Ventech Capital Ii | Major Shareholder | Buy | 28,000 | $10.00 | $280,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for SCYNEXIS (NASDAQ:SCYX)
Latest Headlines for SCYNEXIS (NASDAQ:SCYX)
| Source: |
|
| Date | Headline |
|---|
 | Critical Analysis: SCYNEXIS (SCYX) & Akorn (AKRX)
www.americanbankingnews.com - October 17 at 4:10 AM |
| SCYNEXIS, Inc. (SCYX) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - October 10 at 10:14 AM |
 | In vivo and in vitro data show SCY-078's favorable profile and potential therapeutic benefit
www.nasdaq.com - October 7 at 8:21 AM |
 | SCYNEXIS Presents New Data Further Supporting SCY-078 as a Potential Treatment for Aspergillus and Candida Infections at IDWeek 2017
finance.yahoo.com - October 6 at 9:04 AM |
| SCYNEXIS, Inc. (SCYX) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - October 1 at 7:16 PM |
| Contrasting Corium International (CORI) and SCYNEXIS (SCYX)
www.americanbankingnews.com - October 1 at 10:22 AM |
| SCYNEXIS to Present Data on Lead Antifungal Candidate SCY-078 at IDWeek 2017 - Nasdaq
www.nasdaq.com - September 28 at 12:19 AM |
 | SCYNEXIS to Present Data on Lead Antifungal Candidate SCY-078 at IDWeek 2017
globenewswire.com - September 27 at 5:54 PM |
| SCYNEXIS, Inc. (SCYX) CEO Marco Taglietti Purchases 10,000 Shares
www.americanbankingnews.com - September 25 at 7:36 PM |
| ETFs with exposure to SCYNEXIS, Inc. : September 22, 2017
finance.yahoo.com - September 23 at 5:44 AM |
 | SCYNEXIS (SCYX) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 14 at 9:51 AM |
| What Does SCYNEXIS Inc’s (SCYX) Share Price Indicate?
finance.yahoo.com - September 14 at 9:51 AM |
| SCYNEXIS, Inc. (SCYX) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - September 6 at 6:46 PM |
| ETFs with exposure to SCYNEXIS, Inc. : September 1, 2017
finance.yahoo.com - September 1 at 8:32 AM |
| ETFs with exposure to SCYNEXIS, Inc. : September 1, 2017
finance.yahoo.com - September 1 at 8:32 AM |
| SCYNEXIS to Present at Upcoming Investor Conferences
finance.yahoo.com - August 31 at 9:49 AM |
| SCYNEXIS, Inc. :SCYX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 25 at 11:23 AM |
| Scynexis Q2 - Steady As She Goes - Seeking Alpha
seekingalpha.com - August 23 at 11:22 AM |
| Insider Buying: SCYNEXIS, Inc. (SCYX) CEO Buys 10,000 Shares of Stock
www.americanbankingnews.com - August 17 at 10:24 AM |
| SCYNEXIS, Inc. (SCYX) Given a $14.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - August 16 at 8:02 AM |
| “THINK FUNGUS” - SCYNEXIS Recognizes Fungal Disease Awareness Week Sponsored by the Centers for Disease ... - GlobeNewswire (press release)
globenewswire.com - August 15 at 4:26 PM |
| “THINK FUNGUS” - SCYNEXIS Recognizes Fungal Disease Awareness Week Sponsored by the Centers for Disease Control and Prevention (CDC)
finance.yahoo.com - August 15 at 4:26 PM |
| SCYNEXIS Presents New Data Supporting Oral SCY-078 for the Clinical Treatment of Vulvovaginal Candidiasis ... - GlobeNewswire (press release)
globenewswire.com - August 15 at 6:49 AM |
| SCYNEXIS Presents New Data Supporting Oral SCY-078 for the Clinical Treatment of Vulvovaginal Candidiasis Infections at the 2017 IDSOG Annual Meeting
finance.yahoo.com - August 15 at 6:49 AM |
| SCYNEXIS, Inc. (NASDAQ:SCYX) Insider Gonzalez David Angulo Purchases 10,000 Shares
www.americanbankingnews.com - August 15 at 12:16 AM |
| SCYNEXIS, Inc. (SCYX) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - August 12 at 6:38 PM |
| SCYNEXIS Reports Second Quarter 2017 Financial Results and ... - GlobeNewswire (press release)
globenewswire.com - August 9 at 7:19 AM |
| SCYNEXIS Reports Second Quarter 2017 Financial Results and Provides Company Update
finance.yahoo.com - August 9 at 7:19 AM |
| Roth Capital Analysts Give SCYNEXIS Inc (NASDAQ:SCYX) a $9.00 Price Target
www.americanbankingnews.com - August 7 at 6:20 PM |
| SCYNEXIS to Present at the Canaccord Genuity Growth Conference - GlobeNewswire (press release)
globenewswire.com - August 7 at 3:29 PM |
 | SCYNEXIS to Present at the Canaccord Genuity Growth Conference
feeds.benzinga.com - August 7 at 10:25 AM |
| SCYNEXIS Announces Initiation of Dosing in Phase 2 Study ... - GlobeNewswire (press release)
globenewswire.com - August 4 at 8:01 AM |
| SCYNEXIS Announces Initiation of Dosing in Phase 2 Study Evaluating Oral SCY-078 in Vulvovaginal Candidiasis
finance.yahoo.com - August 4 at 8:01 AM |
| SCYNEXIS, Inc. (SCYX) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - July 18 at 6:56 PM |
| SCYNEXIS, Inc. (SCYX) Coverage Initiated at Roth Capital
www.americanbankingnews.com - July 10 at 9:02 PM |
 | Scynexis (SCYX) Publishes Data on In Vitro Activity of SCYNEXIS ... - StreetInsider.com
www.streetinsider.com - June 15 at 4:32 PM |
| SCYNEXIS, Inc. to Participate in the 2017 BIO International Convention - Nasdaq
www.nasdaq.com - June 13 at 10:46 AM |
| Scynexis: Another Buy Opportunity On The Recent Pullback - Seeking Alpha
seekingalpha.com - May 17 at 7:17 AM |
| Scynexis: Time To Abandon Ship? - Seeking Alpha
seekingalpha.com - May 11 at 1:00 AM |
 | Scynexis reports 1Q loss
marketbeat.com - May 8 at 4:53 PM |
| Scynexis (SCYX) Says Eight Data Presentations at ECCMID Showcase Broad Applicability of SCY-078 - StreetInsider.com
www.streetinsider.com - April 26 at 9:14 PM |
| SCYNEXIS (SCYX) ECCMID SCY-078 Scientific Data Presentation Conference Call - Slideshow
seekingalpha.com - April 26 at 4:13 PM |
 | SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100000 ... - PR Newswire (press release)
www.prnewswire.com - April 21 at 8:14 AM |
 | How These Generic Drugs Stocks are Faring? -- Zynerba Pharma, Patheon, SCYNEXIS, and Flexion Therapeutics
www.bizjournals.com - April 11 at 9:47 AM |
 | INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against SCYNEXIS, Inc. and Encourages Investors with Losses to Contact the Firm
us.rd.yahoo.com - April 4 at 12:22 AM |
| IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against SCYNEXIS, Inc. and Encourages Investors with Losses to Contact the Firm
us.rd.yahoo.com - March 31 at 7:56 PM |
| SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against SCYNEXIS, Inc. (SCYX) and Lead Plaintiff Deadline - May 8, 2017
us.rd.yahoo.com - March 30 at 7:59 PM |
 | INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In SCYNEXIS, Inc. To Contact Brower Piven Before The Lead Plaintiff ...
www.businesswire.com - March 28 at 9:28 AM |
| SCYX INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving SCYNEXIS, Inc. and a Lead Plaintiff Deadline of May 8, 2017
us.rd.yahoo.com - March 24 at 7:34 PM |
| SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in SCYNEXIS, Inc. of Class Action Lawsuit and Upcoming Deadline – SCYX
us.rd.yahoo.com - March 24 at 7:34 PM |
SCYNEXIS (SCYX) Chart for Wednesday, October, 18, 2017
